Philanthropy

8.13.10
Lancet Article Highlights Devastating Lack of Treatment for Neglected Tropical Disease in Africa
The Lancet
In an editorial in the August 13 edition of The Lancet, authors representing the Sabin Vaccine Institute, the World Health Organization (WHO) and the Imperial College of London call for increased supplies of praziquantel for the African continent. Praziquantel is the only commercially available treatment for human schistosomiasis, a devastating neglected tropical disease (NTD) affects an estimated 200-600 million people worldwide, with the vast majority of cases occurring in Africa, and causes chronic anemia and inflammation associated with severe disability among children, adolescents and young adults. Schistosomiasis produces a disease burden that could exceed that of malaria.
Read more

7.28.10
Mapping of Neglected Tropical Diseases Critical to Control and Elimination Efforts
To take full advantage of recent increased financial commitments from some governments, international agencies, and philanthropies, accurate and up-to-date mapping of neglected tropical diseases (NTDs) needs to be implemented to help improve the precision of decision-making in NTD control and elimination, says a new editorial, "The Global Atlas of Helminth Infection: Mapping the Way Forward in Neglected Tropical Disease Control," published July 27 in the open-access journal PLoS Neglected Tropical Diseases.
Read more

7.23.10
NTD Control Program 2010 Annual Meeting
The Access Project
Kigali, Rwanda — The Ministry of Health, in partnership with Columbia University’s Access Project, organized the Neglected Tropical Diseases (NTDs) 2010 annual workshop, which was held at Laico Umubano Hotel on July 20, 2010.
Read more

7.19.10
Dr. Neeraj Mistry named Managing Director, Global Network for Neglected Tropical Diseases
Washington, D.C. – Sabin Vaccine Institute announced today that Dr. Neeraj Mistry has been appointed Managing Director of the Global Network for Neglected Tropical Diseases (Global Network).
Read more

7.15.10
One stop shop for NTD's in the US
PLos Neglected Diseases
The last issue of PLos includes an interesting editorial by Dr. Peter Hotez that highlights the need of a school solely dedicated to Neglected Diseases in our country.
Read the complete editorial here...
Edit

5.25.10
8-point manifesto urges increased control, elimination and R&D efforts against NTDs
Although advances in the control and elimination of neglected infections have been steadily increasing in the past decade—specifically with heightened interest by policy makers, governments, the World Health Organization (WHO), and private philanthropies—more can and must be done, says a new editorial, "'Manifesto' for Advancing the Control and Elimination of Neglected Tropical Diseases," published May 25 in the open-access journal PLoS Neglected Tropical Diseases.
Read more

5.18.10
New ways to tackle neglected tropical diseases
A debate published today in PLoS Medicine examines new approaches to tackling neglected tropical diseases (NTDs), with three viewpoints from experts in the field—including Sabin President Dr. Peter Hotez—arguing which approach shows the most promise.
Read more

5.17.10
Rescuing the 'Bottom Billion' Through Control of the Neglected Tropical Diseases
Population Reference Bureau
With Millennium Development Goal 6, the international community pledged to "combat HIV/AIDS, malaria, and other diseases" throughout the world. Worldwide, 1.4 billion people are infected with one or more of these less-known "other diseases."
Read more
Edit

4.27.10
Neglected Infection Control Is Better Investment than Nuclear Weaponry
For a tiny fraction of the cost of maintaining a nuclear arsenal, the 11 nuclear power states (United States, Russia, United Kingdom, France, China, India, Pakistan, North Korea, Israel, Iran, and possibly Syria) could eliminate neglected infections within their borders
Read more

4.23.10
New initiatives: is the pharmaceutical industry showing more interest in the infectious diseases of poverty?
TropIKA.net
There are growing signs that some of the world’s biggest pharmaceutical companies are devoting more of their research and development efforts to the infectious diseases of poverty. In addition, drugs already in production are increasingly being donated or supplied at reduced cost.
Read more
Edit